409 related articles for article (PubMed ID: 32528403)
21. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
Lambalk CB; Banga FR; Huirne JA; Toftager M; Pinborg A; Homburg R; van der Veen F; van Wely M
Hum Reprod Update; 2017 Sep; 23(5):560-579. PubMed ID: 28903472
[TBL] [Abstract][Full Text] [Related]
22. Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders.
Liu Y; Su R; Wu Y
Front Endocrinol (Lausanne); 2020; 11():605939. PubMed ID: 33519714
[TBL] [Abstract][Full Text] [Related]
23. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
Xiao ZN; Peng JL; Yang J; Xu WM
Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
[TBL] [Abstract][Full Text] [Related]
24. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
25. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
[TBL] [Abstract][Full Text] [Related]
26. GnRH-Agonist Ovulation Trigger in Patients Undergoing Controlled Ovarian Hyperstimulation for IVF with Stop GnRH-Agonist Combined with Multidose GnRH-Antagonist Protocol.
Orvieto R; Nahum R; Frei J; Zandman O; Frenkel Y; Haas J
Gynecol Obstet Invest; 2021; 86(5):427-431. PubMed ID: 34537779
[TBL] [Abstract][Full Text] [Related]
27. IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study.
Ye H; Huang GN; Zeng PH; Pei L
J Assist Reprod Genet; 2009 Mar; 26(2-3):105-11. PubMed ID: 19225876
[TBL] [Abstract][Full Text] [Related]
28. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
Wei LH; Ma WH; Tang N; Wei JH
Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
[TBL] [Abstract][Full Text] [Related]
29. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study.
Huang P; Tang M; Qin A
J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):99-102. PubMed ID: 30321608
[TBL] [Abstract][Full Text] [Related]
30. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
31. Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles.
Dietrich JE; Freis A; Beedgen F; von Horn K; Holschbach V; Liebscher J; Strowitzki T; Germeyer A
Front Endocrinol (Lausanne); 2020; 11():246. PubMed ID: 32411093
[No Abstract] [Full Text] [Related]
32. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
[TBL] [Abstract][Full Text] [Related]
33. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF.
Pu D; Wu J; Liu J
Hum Reprod; 2011 Oct; 26(10):2742-9. PubMed ID: 21778283
[TBL] [Abstract][Full Text] [Related]
34. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
[TBL] [Abstract][Full Text] [Related]
36. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
[TBL] [Abstract][Full Text] [Related]
37. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
[TBL] [Abstract][Full Text] [Related]
38. Fixed Gonadotropin-Releasing Hormone Antagonist Protocol
Dong M; Sun L; Huang L; Wang F; Zhang X; Liu F
Front Endocrinol (Lausanne); 2021; 12():690575. PubMed ID: 34867773
[TBL] [Abstract][Full Text] [Related]
39. A Flexible Multidose GnRH Antagonist versus a Microdose Flare-Up GnRH Agonist Combined with a Flexible Multidose GnRH Antagonist Protocol in Poor Responders to IVF.
Çelik Gİ; Sütçü HK; Akpak YK; Akar ME
Biomed Res Int; 2015; 2015():970163. PubMed ID: 26161425
[TBL] [Abstract][Full Text] [Related]
40. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]